Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these interactions.
Nolan
L
L
Cancer Research UK Clinical Centre, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
Johnson
P W M
PW
Ganesan
A
A
Packham
G
G
Crabb
S J
SJ
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors